Endologix's Powerlink System Granted Canadian Approval.

IRVINE, Calif. -- Endologix, Inc. (Nasdaq:ELGX) today announced that it has been granted approval (Notice of Compliance) on May 27, 2005, by the Canadian Regulatory Agency, Health Canada Therapeutic Products Directorate (HCTPD) to begin marketing the Company's Powerlink(R) System in Canada. The Powerlink System is an endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms (AAA). Endologix estimates that there are approximately 400 AAA ELG cases performed annually in Canada.

In early 2005, the Company introduced the Powerlink System in the U.S. through a strategic market launch after gaining U.S. Food and Drug Administration (FDA) approval in late 2004. The Powerlink System is also approved in Europe and is marketed to selected European countries including Belgium, France, Germany and the United Kingdom through a distribution agreement with Edwards LifeSciences AG.

"While we have successfully performed a handful of procedures under the special access rules in Canada, we now have full marketing approval and will be evaluating our strategic marketing options in the coming months to introduce the Powerlink in this market," said Paul McCormick, Endologix president and chief executive officer.

The Powerlink System is a unibody self-expandable device, with a durable frame made of stainless steel alloy covered with an ePTFE graft. The one-piece bifurcated design featuring a fully supported stent cage was developed to overcome the many shortcomings associated with earlier-generation ELG devices.

About Health Canada, Therapeutic Products Directorate (HCTPD)

HCTPD is the Canadian medical products regulatory authority. Before medical devices can be legally supplied in Canada, they are subject to rigorous review, and manufacturers are obligated to provide evidence to establish quality, safety and efficacy of their device, as well as the standard of manufacture of the goods, for review by HCTPD, prior to approval.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. In October 2004, Endologix received approval to market the Powerlink in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, including risks related to the clinical and payor acceptance of new medical device products, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix, all as more fully described in the risk factors and other matters set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2004, and the Company's other filings with the Securities and Exchange Commission.